$MDT

Medtronic options activity shows heavy call buying ahead of September earnings

Investing.com reports unusual options activity in Medtronic plc ahead of its Sept. 1 earnings. More than 25,000 contracts traded, with calls far exceeding puts (23,524 calls vs. 2,033 puts). A $100 September 2026 call drew about 18,801 contracts. The article cites EPS forecast of $1.39 and revenue of $9.55B.

Original reporting
Published Aug 11, 2026, 3:58 PM UTC
Analysis
alphai AI DeskAI-generated
Added to alphai Aug 11, 2026, 4:06 PM UTC. Informational, not investment advice.
How this was made
alphai summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
alphai market briefMarket movers
Primary signal
$MDT
Bullish
medium confidence
Mentioned
$MDT
Relevance
6/10
alphai data visualization · based on investing.com
Decision brief

The 30-second read

$MDTBullishMed
01

Why it matters

Traders can use the call/put imbalance and the concentration in the $100 Sept. 2026 call as a near-term sentiment and volatility gauge into the earnings date, but it is not a fundamental earnings revision.

02

Market read

Options positioning is strongly bullish into earnings, which can increase event-day volatility and raise the probability of a larger-than-usual post-earnings repricing.

03

What to watch

The article provides options-flow signals but no new fundamental update; implied volatility is only moderately elevated, so the market may already be pricing a move.

Relevance 6/10Novelty 4/10Timing: ahead of Sept. 1 earnings (options flow reported today)

Background

The piece frames unusual options activity as an “event bet” ahead of Medtronic’s Sept. 1 earnings, citing specific contract volumes and implied volatility changes.

Company-level read

Ticker impact

$MDTBullishMedium confidence
Context

Medtronic options show heavy call buying ahead of its Sept. 1 earnings, with 23,524 calls vs 2,033 puts and a dominant $100 call.

Expected impact

Near-term upside bias into earnings, but with event-driven volatility that can reverse quickly if results disappoint.

Evidence & confidence

The article cites concentrated, fresh bullish call activity (not just rolling) and a large call/put imbalance, which typically precedes larger post-earnings repricing.

Market effects

If MDT’s earnings surprise is large, it can lift sentiment for medical device peers with similar earnings timing and valuation sensitivity.

Limited direct regional spillover; primarily a single-name event trade.

Moderate, as MDT is a large-cap global healthcare name but the catalyst is company-specific earnings positioning.

Counterpoint

Call buying can reflect hedging or volatility trades rather than a true directional earnings bet, so the move may not be sustained post-print.

Key entities

  • Medtronic plc

    Subject of the article, with reported unusual call-heavy options activity ahead of Sept. 1 earnings.

  • September 1, 2026 earnings

    The scheduled catalyst date referenced as the reason for the options positioning.

Related articles

$DHRMedAI 8/10

Danaher vs. Medtronic: Which Healthcare Recovery Story Has More Upside?

Danaher (DHR) and Medtronic (MDT) report recovery signs. DHR benefits from life sciences demand, with bioprocessing orders growing mid-teens. MDT shows highest annual revenue growth in 10 years, with Q4 revenue at $9.8B and FY26 at $36.4B. MDT's cardiac segment grew 78% globally, driven by cardiac ablation solutions. Both companies face challenges, with MDT's growth concentrated in a few platforms and DHR's revenue delayed into next year.

$MDTMedAI 8/10

Medtronic vs. Tenet Healthcare: Which Healthcare Stock Offers Better Long-Term Growth?

Medtronic (MDT) and Tenet Healthcare (THC) present distinct growth prospects. MDT reported its highest annual revenue growth in a decade, driven by cardiac ablation solutions and investments in innovation. THC saw a 52.2% increase in adjusted EPS and 6.8% revenue growth, with margin expansion in hospitals. Investors must choose between MDT's innovation-led recovery and THC's operational improvements.

$ISRGMed

Johnson & Johnson and Medtronic Enter the Fray, Squeezing Market Share as Intuitive Surgical Faces Its Biggest Challenge in Recent Years

Intuitive Surgical (ISRG) stock fell 30% in 2026 due to weak guidance, competition, and high valuations. Q2 revenue grew 19%, but full-year procedure growth guidance was below expectations. Competitors like Johnson & Johnson and Medtronic are entering the market, raising concerns about ISRG's market share. Analysts note high valuation multiples and slowing growth may pressure the stock further.

$JNJMed

Johnson & Johnson vs. Medtronic: Which Healthcare Stock Is Better Positioned After Earnings?

Johnson & Johnson (JNJ) reported fiscal Q2 2026 sales of $25.31B (+6.6% YoY) and adjusted EPS of $2.90, both above estimates, and raised full-year guidance to a $101.1B midpoint and $11.68 adjusted EPS. Medtronic (MDT) posted its fastest annual revenue growth in a decade, with FY26 revenue $36.4B and adjusted revenue $36.3B. Article compares post-earnings positioning and risks.